Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
International Forum of Allergy & Rhinology|January 8, 2025
Biodiversity of the Bacterial and Fungal Microbiome and Associated Inflammatory Cytokine Profile in Chronic RhinosinusitisHong-Ho Yang, Carra A Simpson, Meera Srivastava, et al.
Cancer|February 6, 2020
A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbesSaroj K Basak, Alakesh Bera, Alexander J Yoon, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 28, 2023
MK2 nonenzymatically promotes nuclear translocation of caspase-3 and resultant apoptosisOthello Del Rosario, Karthik Suresh, Medha Kallem, et al.
Physiological Genomics|March 6, 2023
Tumor MK2 transcript levels are associated with improved response to chemotherapy and patient survival in non-small cell lung cancerKarthik Suresh, Othello Del Rosario, Medha Kallem, et al.
Journal for Immunotherapy of Cancer|May 30, 2024
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypesNoam Levin, Sanghyun P Kim, Charles A Marquardt, et al.
Nature Medicine|July 11, 2024
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim resultsMaria Parkhurst, Stephanie L Goff, Frank J Lowery, et al.
Cancer Cell|December 1, 2023
Phenotypic signatures of circulating neoantigen-reactive CD8<sup>+</sup> T cells in patients with metastatic cancersRami Yossef, Sri Krishna, Sivasish Sindiri, et al.
Nature Medicine|April 1, 2025
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trialFrank J Lowery, Stephanie L Goff, Billel Gasmi, et al.
Cancer Immunology Research|June 24, 2022
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid TumorsSanghyun P Kim, Nolan R Vale, Nikolaos Zacharakis, et al.
Pageof 5